Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts

Endocrinology

Volumn 149, Issue 8, 2008, Pages 4043-4050

  Tabbi Anneni, Imene ^a   Buchanan, Jonathan ^a   Cooksey, Robert C ^a   Abel, E Dale ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Program in Human Molecular Biology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PALMITIC ACID; PROTEIN KINASE B; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GLUCOSE TOLERANCE TEST; GLYCOLYSIS; HEART MUSCLE; HEART PERFORMANCE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN SENSITIVITY; ISOLATED HEART; MALE; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BODY WEIGHT; CAPTOPRIL; CARDIOVASCULAR DISEASES; DRUG EVALUATION, PRECLINICAL; GLUCOSE; HEART; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MYOCARDIUM; OBESITY; ORGAN CULTURE TECHNIQUES; ORGAN SIZE; OXYGEN CONSUMPTION; SIGNAL TRANSDUCTION;

EID: 47949106019     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1646     Document Type: Article

References (42)

1. Wild SH, Byrne CD 2006 ABC of obesity. Risk factors for diabetes and coronary heart disease. BMJ 333:1009-1011
2. Spinler SA 2006 Challenges associated with metabolic syndrome. Pharmacotherapy 26:209S-217S
3. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM 2004 The evolving diabetes burden in the United States. Ann Intern Med 140:945-950
4. Lim HS, MacFadyen RJ, Lip GY 2004 Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med 164:1737-1748
5. Marrero MB, Fulton D, Stepp D, Stern DM 2004 Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 24:2009-2013
6. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP 1997 Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100:2158-2169
7. Carvalheira JB, Calegari VC, Zecchin HG, Nadruz Jr W, Guimaraes RB, Ribeiro EB, Franchini KG, Velloso LA, Saad MJ 2003 The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase-and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology 144:5604-5614
8. Scheen AJ 2004 Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30:487-496
9. Fang ZY, Prins JB, Marwick TH 2004 Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543-567
10. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED 2004 Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53:2366-2374
11. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, Abel ED 2007 Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56:2457-2466
12. An D, Rodrigues B 2006 Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291:H1489-H1506
13. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ 2004 Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109:2191-2196
14. Desrois M, Sidell RJ, Gauguier D, King LM, Radda GK, Clarke K 2004 Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart. Cardiovasc Res 61:288-296
15. Nascimento EB, Fodor M, van der Zon GC, Jazet IM, Meinders AE, Voshol PJ, Vlasblom R, Baan B, Eckel J, Maassen JA, Diamant M, Ouwens DM 2006 Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes 55:3221-3228
16. Ouwens DM, Boer C, Fodor M, de Galan P, Heine RJ, Maassen JA, Diamant M 2005 Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 48:1229-1237
17. Ouwens DM, Diamant M, Fodor M, Habets DD, Pelsers MM, El Hasnaoui M, Dang ZC, van den Brom CE, Vlasblom R, Rietdijk A, Boer C, Coort SL, Glatz JF, Luiken JJ 2007 Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 50:1938-1948
18. Park SY, Cho YR, Kim HJ, Higashimori T, Danton C, Lee MK, Dey A, Rothermel B, Kim YB, Kalinowski A, Russell KS, Kim JK 2005 Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 54:3530-3540
19. Boudina S, Abel ED 2006 Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 21:250-258
20. Martinez LA, Villalobos-Molina R 2003 Early and chronic captopril or losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats. Arch Med Res 34:357-361
21. Arikawa E, Ma RC, Isshiki K, Luptak I, He Z, Yasuda Y, Maeno Y, Patti ME, Weir GC, Harris RA, Zammit VA, Tian R, King GL 2007 Effects of insulin replacements, inhibitors of angiotensin, and PKCβ's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes 56:1410-1420
22. Lund AK, Goens MB, Kanagy NL, Walker MK 2003 Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure. Toxicol Appl Pharmacol 193:177-187
23. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED 2005 Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146:5341-5349
24. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, Abel ED 2002 Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109:629-639
25. Carvalho CR, Thirone AC, Gontijo JA, Velloso LA, Saad MJ 1997 Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46:1950-1957
26. Duarte J, Martinez A, Bermejo A, Vera B, Gamez MJ, Cabo P, Zarzuelo A 1999 Cardiovascular effects of captopril and enalapril in obese Zucker rats. Eur J Pharmacol 365:225-232
27. Henriksen EJ 2007 Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 293:R974-R980
28. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M 2002 ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40:329-334
29. Dal Ponte DB, Fogt DL, Jacob S, Henriksen EJ 1998 Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. Metabolism 47:982-987
30. Arbin V, Claperon N, Fournie-Zaluski MC, Roques BP, Peyroux J 2003 Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats. J Cardiovasc Pharmacol 41:254-264
31. Carley AN, Severson DL 2005 Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734:112-126
32. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ 2007 Cardiovascular metabolic syndrome-an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 9:218-232
33. Hafstad AD, Khalid AM, How OJ, Larsen TS, Aasum E 2007 Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice. Am J Physiol Endocrinol Metab 292:E1288-E1294
34. Houstis N, Rosen ED, Lander ES 2006 Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948
35. Jay D, Cuella A, Jay E 1995 Superoxide dismutase activity of the captopril-iron complex. Mol Cell Biochem 146:45-47
36. Pi XJ, Chen X 1989 Captopril and ramiprilat protect against free radical injury in isolated working rat hearts. J Mol Cell Cardiol 21:1261-1271
37. Dyntar D, Eppenberger-Eberhardt M, Maedler K, Pruschy M, Eppenberger HM, Spinas GA, Donath MY 2001 Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 50:2105-2113
38. Backlund T, Palojoki E, Saraste A, Gronholm T, Eriksson A, Lakkisto P, Vuolteenaho O, Nieminen MS, Voipio-Pulkki LM, Laine M, Tikkanen I 2003 Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc Res 57:727-737
39. Lapointe N, Tsoporis JN, Parker TG, Blais Jr C, Adam A, Rouleau D, Slaughter G, Clement R, Deschepper CE, Rouleau JL 2003 Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure. Mol Cell Biochem 254:235-245
40. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, Abel ED 2005 Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112:2686-2695
41. Kewalramani G, An D, Kim MS, Ghosh S, Qi D, Abrahani A, Pulinilkunnil T, Sharma V, Wambolt RB, Allard MF, Innis SM, Rodrigues B 2007 AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. J Mol Cell Cardiol 42:333-342
42. Wang MY, Unger RH 2005 Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. Am J Physiol Endocrinol Metab 288:E216-E221